Eli Lilly seals $1bn genetics deal
17-12-2020
SCOTUS refuses to hear Eli Lilly patent win
16-06-2020
Eli Lilly secures exclusive rights to chronic pain treatment
03-06-2019
Jonathan Weiss / Shutterstock.com
Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Dermira, merger, glycopyrronium, lebrikizumab, blockbuster
